COVAXIN Demonstrates Overall Interim Clinical Efficacy of 78%

No Comments
Posted in Featured, National, Northeast

Bharat Biotech and ICMR on April 21 announced interim results from Phase – 3 trials of COVAXIN. It has reported overall interim clinical efficacy of 78 per cent of Covaxin.

It said that the efficacy of the vaccine against severe COVID-19 disease was 100 per cent.

In a statement, the company said, the second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.

It said, due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease.

Tags: , , ,

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The reCAPTCHA verification period has expired. Please reload the page.

More Articles